



## Anthony Moore, Ph.D.

Toxicologist

• Director-Coordination, Asia Pacific Organization for Cancer Prevention, Korean Cancer Center, Goyang, Korea.

### **Associate Editor**

## Prof. David Roder

Professor of Cancer Epidemiology

Q Chair Cancer Epidemiology and Population Health, Beat Cancer Project, University of South Australia, Adelaide, Australia

Ca.linkedin.com/in/david-roder-54699329

ズ roder@internode.on.net

### L Dr. Abhishek Shankar

Preventive Oncology, Radiation Oncology

**Q** Assistant Professor

Department of Preventive Oncology,

Dr B R Ambedkar Instituute Rotary Cancer Hospital

All India Institute of Medical Sciences,

Delhi, India

🐱 doc.abhishankar@gmail.com

+ More

### Founder

### L Yip Cheng-Har, MD, FACS

Surgery

♀ Prof. of Gynaecological Oncology
 Faculty of Medicine, University Tunku Abdul Rahman, Kuala Lumpur, Malysiaa
 ☑ chenghar.yip@gmail.com

+ More

## L Keun-Young Yoo, MD, Ph.D.

Prof. of Cancer Epidemiology

President, APOCP

President, Armed Forces Capital Hospital

Professor, Seoul National University College of Medicine, Seoul, Korea

🔀 bkkyyoo@gmail.com

## 👤 Kazuo Tajima, MD

Pathology

♀ Prof. of Pathology
 Director, Aichi Cancer Center Research Institute, Ozaka, Japan
 ☑ ktajima@clin.medic.mie-u.ac.jp

+ More

## L Prof. You Lin Qiao, M.D. Ph.D.,

Epidemiology

♥ Director, Dept. of Cancer Epidemiology
 Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
 Beijing, China
 ➤ qiaoy@cicams.ac.cn

### International Advisory Board

### L Prof. Niveen Abu-Rmeileh

**Community Medicine** 

 ♥ Associate prof. of Community Medicine Institute of Community and Public Health, Birzeit University,
 Birzeit – Palestine
 ▼ nrmeileh@gmail.com

### + More

## 💄 Prof. Rema Gvamichava

Prof. of Surgery

♥ A. Gvamichava National Cancer Center,
 Tbilisi State Medical University
 Tbilisi, Georgia
 ☑ doctorrema@yahoo.com

### L Prof. Mohammad Esmail Akbari

Prof. of Surgery

♥ Cancer Research Center,
 Shahid Beheshti University of Medical Scinces, Tehran, Iran
 ▼ profmeakbari@gmail.com

## L Prof. Ali Montazeri

Public Health

Q Health Metrics Research Center, Institute for Health Sciences Research, ACECR, Iran

X montazeri@acecr.ac.ir

h-index: 65

+ More

## L Dr. Shahab Uddin

**Cancer Biology** 

Hamad Medical Corporation
 Academic Health System
 Doha, Qatar
 Suddinkhan@gmail.com

+ More

♥ Radiation Oncology Research
 William Beaumont Research Institute, USA
 ➤ pravin.kesarwani@gmail.com

#### + More

## 👤 Dr. Parastoo Hajian

#### Radiation Oncology

♥ Dept. of Radiotherapy, Medical School, Shahid Beheshti University of Medical Sciences, Department of radiation oncology, Shohad-e-Tajrish Hospital ▼ parastoo.hajjan@yahoo.com

### Epidemiology (Incidence, Prevalence, Survival, Statistical modeling, GIS)

### **Editorial Board**

### L Dr. Anton Barchuk

Thoracic surgery

 Petrov Research Institute of Oncology Saint Petersburg, Russian Federation
 barchuk.anton@gmail.com

## 👤 Dr. Munir Abu-Helalah

#### Epidemiology

• Regional Director Middle East, North Africa and Central Asia Global Academy for Health Sciences Adjunct Associate Professor of Epidemiology and Preventive Medicine, AlFaisal University, KSA Consultant Chronic Diseases Control& Prevention and Medical Screening

🔀 mabuhelalah@yahoo.co.uk

## L Prof. Nurbek Igissinov

Oncology

♥ Chairman of Public Association
 Department of Surgical Diseases of Internship
 Central Asian Cancer Institute
 Astana Medical University
 Astana, The Republic of Kazakhstan.
 ▼ n.igissinov@gmail.com

## L Prof. Le Tran Ngoan

Occupational Health

♥ International University of Health and Welfare, Japan and Hanoi Medical University, Viet Nam

🔀 letranngoan@yahoo.com

## L Prof. Omran S. Habib

Social Medicine

♥ Department of Community Medicine, College of Medicine, University of Basrah, Basrah, Iraq ▼ omran49\_basmed@yahoo.com

+ More

## L Dr. Rahmatollah Moradzadeh

Epidemiology

♥ Assistant Professor Department of Epidemiology, School of Public Health, Arak University of Medical Sciences, Arak. Iran

### Cancer Genetics (karyotyping and molecular genetics)

### **Editorial Board**

### L DR. Elsayed I Salim

♥ Faculty of Science, Tanta University, Tanta, Egypt
 ➤ elsalem\_777@yahoo.com

## L Dr. Reza Shirkohi

Medical Genetic

♀ Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran

🔀 r\_shirkoohi@yahoo.com

## L Prof. Mehrnoosh Doroudchi

#### Immunology

♥ Associate Professor of Immunology
 Director of Memory T cell Laboratory
 Department of Immunology, School of Medicine
 Shiraz University of Medical Sciences, Shiraz-Iran
 ➤ mdoroud@sums.ac.ir

+ More

L Prof. Manoochehr Makvandi
Virology
<ul> <li>Virology Dept. Ahwaz University of Medical Sciences, Ahwaz, Iran</li> <li>manoochehrmakvandi29@yahoo.com</li> </ul>
+ More

Molecular and Cellular aspect (Inflammation, Oxidative stress, studies of cell lines)

### **Editorial Board**

### L Prof. Jalal Pourahmad

Toxicologist

♀ School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Scholar.google.com/citations?user=SLqpnmoAAAAJ&hl=en

🔀 pourahmad.j@sbmu.ac.ir

0000-0002-4555-4168

## L Prof. Ravi Mehrotra

Cytopathology

♥ National Institute of Cancer Prevention and Research
 WHO-FCTC Global Hub for information on smokeless tobacco products
 (Institute of Cytology and Preventive Oncology-ICMR)
 Department of Health Research, Noida, India
 ▼ rmehrotra@icmr.org.in

### + More

## L Prof.. Muhammad Asif Qureshi

Tumor Immunology

<ul> <li>Department of Pathology, Dow International Medical College, Dow University of Health Sciences (OJHA CAMPUS), Karachi, Pakistan</li> <li>www.unimedizin-mainz.de/tim/mitarbeiter.html</li> <li>asif@asifqureshi.com</li> <li>+923002185053</li> </ul>
+ More
L Dr. Pratheeshkumar Poyil
Biotechnology ♥ Associate Scientist King Faisal Specialist Hospital & Research Center Riyadh, Saudi Arabia ▼ ppratheeshkumar@gmail.com
+ More
L Dr. Ajaz Ahmad Bhat
Cancer Biology
<ul> <li>Interim Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar</li> <li>abhat@sidra.org</li> <li>0000-0003-3640-6275</li> </ul>
+ More

## L Dr. Houssein Ghahramani

Biochemistry

*♀ sвм∪* **⊠** ghahremani@sbmu.ac.ir Solume & Issue: Volume 17, Issue 4, April 2016  $\overline{M}$ Number of Articles: 121

#### **Recent Progress in Triple Negative Breast Cancer Research**

Pages 1595-1608 Fatima Zahra Mouh; Mohammed El Mzibri; Mariam Amrani View Article PDF 620.29 K

#### HER-2 Positive Breast Cancer - a Mini-Review

Pages 1609-1615 Hafiz Muhammad Asif; Sabira Sultana; Saeed Ahmed; Naheed Akhtar; Muhammad Tariq View Article PDF 480.01 K

#### Three Weekly Versus Weekly Cisplatin as Radiosensitizer in Head and Neck Cancer: a Decision Dilemma

Pages 1617-1623 Preety Negi; Pamela Alice Kingsley; Himanshu Srivastava; Surender Kumar Sharma

View Article 🔀 PDF 490.52 K

#### Multimodality Treatment for Patients with Node-Positive Prostate Cancer: the Role of Radiation Therapy

Pages 1625-1630 Satoru Ochiai; Yoshihito Nomoto; Shigeki Kobayashi; Yasufumi Yamashita; Yui Watanabe; Yutaka Toyomasu; Tomoko Kawamura; Akinori Takada; Noriko II; Hajime Sakuma

View Article DPF 451.18 K

#### **Diagnosis of Helicobacter pylori Infection**

Pages 1631-1635 Taweesak Tongtawee; Soraya Kaewpitoon; Natthawut Kaewpitoon; Chavaboon Dechsukhum; Wilairat Leeanansaksiri; Ryan A Loyd; Likit Matrakool; Sukij Panpimanmas

View Article DPF 205.63 K

#### **Clinical Features of Oxaliplatin Induced Hypersensitivity Reactions and Therapeutic Approaches**

Pages 1637-1641 Nusrat Bano; Rahila Najam; Faaiza Qazi; Ahmed Mateen

View Article 🔀 PDF 370.51 K

### Ganglioside as a Therapy Target in Various Types of Cancer

Pages 1643-1647

Elmira Safaie Qamsari; Alireza Nourazarian; Salman Bagheri; Morteza Motallebnezhad

View Article 🔀 PDF 564.81 K

#### Anti-Cancer Effects of Green Tea by Either Anti- or Pro- Oxidative Mechanisms

Pages 1649-1654

Sumio Hayakawa; Kieko Saito; Noriyuki Miyoshi; Tomokazu Ohishi; Yumiko Oishi; Mamoru Miyoshi; Yoriyuki Nakamura

View Article 🔀 PDF 592.3 K

## Celecoxib, a COX-2 Selective Inhibitor, Induces Cell Cycle Arrest at the G2/M Phase in HeLa Cervical Cancer Cells

Pages 1655-1659

Agustina Setiawati

View Article 🔀 PDF 797.75 K

## Efficacy and Safety of Neurokinin-1 Receptor Antagonists for Prevention of Chemotherapy-Induced Nausea and Vomiting: Systematic Review and Meta-analysis of Randomized Controlled Trials

Pages 1661-1675

Dong-Mei Yuan; Qian Li; Qin Zhang; Xin-Wu Xiao; Yan-Wen Yao; Yan Zhang; Yan-Ling Lv; Hong-Bin Liu; Tang-Feng Lv; Yong Song

View Article 🔀 PDF 1.47 M

#### **Quality of Life among Breast Cancer Patients In Malaysia**

Pages 1677-1684 Sri Ganesh; Munn-Sann Lye; Fen Nee Lau View Article PDF 653.2 K

#### Dosimetric Characteristics of 6 MV Modified Beams by Physical Wedges of a Siemens Linear Accelerator

Pages 1685-1689 Mansour Zabihzadeh; Mohammad Javad Tahmasebi Birgani; Mojtaba Hoseini-Ghahfarokhi; Sholeh Arvandi; Seyed Mohammad Hoseini; Mahbube Fadaei

View Article 🔀 PDF 573.35 K

### Data Mining for Identification of Molecular Targets in Ovarian Cancer

Pages 1691-1699 Vanessa Villegas-Ruiz; Sergio Juarez-Mendez View Article PDF 1.95 M

# Global Incidence and Mortality Rates of Stomach Cancer and the Human Development Index: an Ecological Study

Pages 1701-1704 Salman Khazaei; Shahab Rezaeian; Mokhtar Soheylizad; Somayeh Khazaei; Azam Biderafsh

View Article 🔀 PDF 539.4 K

#### Association of Viral Infections with Risk of Human Lymphomas, Egypt

Pages 1705-1712 Dalia Y Kadry; Amira M Khorshed; Reham A Rashed; Nadia M Mokhtar

View Article 🔀 PDF 1.32 M

# Implementation of Health Behavior Education Concerning Liver Flukes among Village Health Volunteers in an Epidemic Area of Thailand

Pages 1713-1716

Soraya J Kaewpitoon; Ratana Rujirakul; Parichart Wakkuwattapong; Likit Matrakool; Taweesak Tongtawee; Jun Norkaew; Jirawoot Kujapun; Wilas Kampangsri; Natthawut Kaewpitoon

View Article 🔀 PDF 3.59 M

Parental Experiences with Chemotherapy-Induced Alopecia among Childhood Cancer Patients in Indonesia Pages 1717-1723 Stefanus Gunawan; Chloe ten Broeke; Peter van de Ven; Marijn Arnoldussen; Gertjan Kaspers View Article PDF 515.5 K

#### Screening for Del 185 AG and 4627C>A BRCA1 Mutations in Breast Cancer Patients from Lahore, Pakistan

Pages 1725-1727 Faiza Aziz; Warda Fatima; Saqib Mahmood; Samina Khokher View Article PDF 504.49 K

## Correlation between RAS Test Results and Prognosis of Metastatic Colorectal Cancer Patients: a Report from Western Iran

Pages 1729-1732 Mehrdad Payandeh; Babak Shazad; Masoud Sadeghi; Maryam Shahbazi View Article PDF 393.98 K

### Prevalence of Tobacco and Alcohol Consumption among Fishermen in Udupi Taluk, Karnataka, India: a Cross-Sectional Study

Pages 1733-1737 Prasad Pramod Rane; Prakash Narayanan; VS Binu; Bhaskaran Unnikrishnan View Article PDF 384.84 K

#### Evaluation of Anticancer Activity of Curcumin Analogues Bearing a Heterocyclic Nucleus

Pages 1739-1744 Mohamed Jawed Ahsan

View Article 🔀 PDF 1.14 M

#### Survival in Head and Neck Cancers - Results of A Multi- Institution Study

Pages 1745-1754

View Article 🔀 PDF 1.27 M

## Predictive Effect of Preoperative Anemia on Long-Term Survival Outcomes with Non-Muscle Invasive Bladder Cancer

Pages 1755-1758 Orcun Celik; Murat Akand; Mehmet Zeynel Keskin; Rahmi Gokhan Ekin; Mehmet Yoldas; Yusuf Ozlem Ilbey View Article PDF (449.39 K)

#### Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand

Pages 1759-1767 Chalermrat Potikul; Siriwan Tangjitgamol; Jakkapan Khunnarong; Sunamchok Srijaipracharoen; Thaovalai Thavaramara; Kamol Pataradool

View Article DPF 623.14 K

## Immunohistochemical Differentiation between Urothelial Papillomas and Papillary Neoplasms of Low Malignant Potential of the Urinary Bladder

Pages 1769-1772 Mohammed Alrashidy; Tarek Abdel Baky View Article PDF 1.18 M

## Peripheral Blood Lymphocytes as In Vitro Model to Evaluate Genomic Instability Caused by Low Dose Radiation

Pages 1773-1777 Shikha Tewari; Kainat Khan; Nuzhat Husain; Madhup Rastogi; Surendra P Mishra; Anoop K Srivastav View Article PDF 2.71 M

#### Breaking Bad News: Patient Preferences and the Role of Family Members when Delivering a Cancer Diagnosis

Pages 1779-1784 Abha Rao; Maria Ekstrand; Elsa Heylen; Girish Raju; Arun Shet View Article PDF 549.65 K

# Lack of Utility of Cytokeratins in Differentiating Pseudocarcinomatous Hyperplasia of Granular Cell Tumors from Oral Squamous Cell Carcinoma

Pages 1785-1787 Kamal Al-Eryani; Jumana Karasneh; Parish P Sedghizadeh; Saravanan Ram; Faleh Sawair View Article PDF 1.22 M

### Evaluation of KiSS1 as a Prognostic Biomarker in North Indian Breast Cancer Cases

Pages 1789-1795

Richa Singh; Madan Lal Brahma Bhatt; Saurabh Pratap Singh; Vijay Kumar; Madhu Mati Goel; Durga Prasad Mishra; Rajendra Kumar

View Article 🔀 PDF 712.93 K

#### Informational Needs of Women with Breast Cancer Treated with Chemotherapy

Pages 1797-1800 Elie Abi Nader; Hampig Raphael Kourie; Marwan Ghosn; Fadi El Karak; Joseph Kattan; Georges Chahine; Fadi Nasr View Article DPF 398.49 K

# Circulating Cell-free miRNA Expression and its Association with Clinicopathologic Features in Inflammatory and Non- Inflammatory Breast Cancer

Pages 1801-1810

K Hamdi; J Blancato; D Goerlitz; MD Islam; B Neili; A Abidi; A Gat; F Ben Ayed; S Chivi; CA Loffredo; I Jillson; A Benammar Elgaaied; R Marrakchi

View Article 🔀 PDF 768.3 K

# Evaluation of Cholangiocarcinoma Risk and its Related Factors in Wetland Geographical Communities of Ubon Ratchathani, Thailand

Pages 1811-1815

Nopparat Songserm; Somkiattiyos Woradet; Onanong Bureelerd; Pattaraporn Charoenbut

View Article 🔀 PDF 424.97 K

## Ginsenoside-Rh2 Inhibits Proliferation and Induces Apoptosis of Human Gastric Cancer SGC-7901 Side Population Cells

Pages 1817-1821 Jun Qian; Jing Li; Jian-Guang Jia; Xin Jin; Da-Jun Yu; Chen-Xu Guo; Bo Xie; Li-Yu Qian View Article DF 1.57 M

### Dryocrassin ABBA Induces Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells Through a Caspase-Dependent Mitochondrial Pathway

Pages 1823-1828 Zhe Jin; Wen-Fei Wang; Jian-Ping Huang; He-Meng Wang; Han-Xun Ju; Ying Chang View Article PDF 3.09 M

#### A Pilot Study on Screening of BRCA1 Mutations (185delAG, 1294del40) in Nepalese Breast Cancer Patients

Pages 1829-1832 Bibek Bhatta; Roshina Thapa; Sanjay Shahi; Yogesh Bhatta; Dipendra Raj Pandeya; Bal Hari Poudel View Article DF 410.87 к

### Multiple Myeloma: a Retrospective Analysis of 61 Patients from a Tertiary Care Center

Pages 1833-1835

Sadia Sultan; Syed Mohammed Irfan; Saira Parveen; Hamza Ali; Maria Basharat

View Article DPF 342.69 K

## Colon Cancer among Older Saudis: Awareness of Risk Factors and Early Signs, and Perceived Barriers to Screening

Pages 1837-1846

Yasmine Samir Galal; Tarek Tawfik Amin; Abdulelah Khalid Alarfaj; Abdulaziz Abdullah Almulhim; Abdullah Abdulmohsen Aljughaiman; Abdulrhaman Khaled Almulla; Rehab Ahmed Abdelhai

View Article 🔀 PDF 555.91 K

## Clinical Significance of Smudge Cells in Peripheral Blood Smears in Hematological Malignancies and Other Diseases

Pages 1847-1850

Chih-Chun Chang; Jen-Tang Sun; Tse-Hsuan Liou; Chin-Fu Kuo; Chia- Hao Bei; Sheng-Jun Lin; Wei-Ting Tsai; N-Chi Tan; Ching-Biau Liou; Ming- Jang Su; Tzung-Hai Yen; Fang-Yeh Chu

View Article DF 410.52 K

# Effects of SULT1A1 Copy Number Variation on Estrogen Concentration and Tamoxifen-Associated Adverse Drug Reactions in Premenopausal Thai Breast Cancer Patients: A Preliminary Study

Pages 1851-1855

Wanaporn Charoenchokthavee; Duangchit Panomvana Na Ayudhya; Virote Sriuranpong; Nutthada Areepium

View Article DF 399.95 K

## Frequency and Pattern of Bone Marrow Infiltration in Classical Hodgkin's Lymphoma: Experience from Southern Pakistan

Pages 1857-1859 Sadia Sultan; Syed Mohammed Irfan; Saira Parveen; Syeda Amna Haider; Mahira Masood View Article PDF 353.06 К

#### Improving the Accuracy of Early Diagnosis of Thyroid Nodule Type Based on the SCAD Method

Pages 1861-1864 Hadi Raeisi Shahraki; Saeedeh Pourahmad; Shahram Paydar; Mohsen Azad View Article PDF 450.46 K

#### Adenosine Deaminase - a Novel Diagnostic and Prognostic Biomarker for Oral Squamous Cell Carcinoma

Pages 1865-1868 Deepak Chandrakant Kelgandre; Jigna Pathak; Shilpa Patel; Pramod Ingale; Niharika Swain View Article 🔀 PDF 1.48 M

### Errors in Surgical Pathology Reports: a Study from a Major Center in Pakistan

Pages 1869-1874

Zubair Ahmad; Romana Idrees; Nasir Uddin; Arsalan Ahmed; Saira Fatima

View Article DF 464.59 K

#### Rural Women's Awareness about Breast Cancer in Southeastern Iran: a Cross-Sectional Study

Pages 1875-1879 Abbas Balouchi; Hosien Shahdadi; Esra AlKhasawneh; Abdolghani Abdollahimohammad; Mohammadreza Firouzkouhi; Hamed Sarani; Afsaneh Gorgij

View Article 🔀 PDF 368.52 K

#### Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival

Pages 1881-1886 Heru Pradjatmo; Heru Pradjatmo View Article PDF 309.8 K

## Micro RNA 34a and Let-7a Expression in Human Breast Cancers is Associated with Apoptotic Expression Genes

Pages 1887-1890 Behzad Mansoori; Ali Mohammadi; Solmaz Shirjang; Elham Baghbani

View Article 🔀 PDF 455.02 K

## Anti-Cancer Effects of Imperata cylindrica Leaf Extract on Human Oral Squamous Carcinoma Cell Line SCC-9 in Vitro

Pages 1891-1898 Rohini Keshava; Nagesh Muniyappa; Rajalakshmi Gope; Ananthanarayana Saligrama Ramaswamaiah View Article 🔀 PDF 1.11 M

Characteristics of Incident Testicular Cancer in Lebanon - 1990-2015 Single Institutional Experience

Pages 1899-1902 Tarek Assi; Fadi Nasr; Elie El Rassy; Toni Ibrahim; Hicham Jabbour; Georges Chahine

View Article DF 444.82 K

### Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study

Pages 1903-1907

Kittichet Phiphatpatthamaamphan; Ratha-korn Vilaichone; Sith Siramolpiwat; Anupong Tangaroonsanti; Soonthorn Chonprasertsuk; Patommatat Bhanthumkomol; Bubpha Pornthisarn; Varocha Mahachai

View Article 🔀 PDF 464.35 K

### Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey

Pages 1909-1915

Macit Arvas; Yavuz Salihoglu; Veysel Sal; Tayfun Gungor; Hamdullah Sozen; Ilker Kahramanoglu; Samet Topuz; Fuat Demirkiran; Cem Iyibozkurt; Tugan Bese; Burcin Salman Ozgu; Dogan Vatansever; Nedim Tokgozoglu; Sinan Berkman; Hasan Turan; Ergin Bengisu; Nigar Sofiyeva; Irem Demiral; Mutlu Meydanli

View Article 🔀 PDF 607.36 K

### Screening for Lynch Syndrome in Young Colorectal Cancer Patients from Saudi Arabia Using Microsatellite Instability as the Initial Test

Pages 1917-1923

Masood Alqahtani; Fabienne Grieu; Amerigo Carrello; Benhur Amanuel; Miral Mashour; Rabab Alattas; Khalid Saleh; Abdulmalik Alsheikh; Sarah Alqahtani; Barry Iacopetta

View Article 🔀 PDF 7.33 M

# Variant Alleles in XRCC1 Arg194Trp and Arg399Gln Polymorphisms Increase Risk of Gastrointestinal Cancer in Sabah, North Borneo

Pages 1925-1931 Noor Hanis Abu Halim; Eric Tzyy Jiann Chong; Jitt Aun Chuah; Edwin Un Hean See; Kek Heng Chua; Ping-Chin Lee View Article PDF 558.52 K

#### High Cadmium Levels in Cured Meat Products Marketed in Nigeria - Implications for Public Health

Pages 1933-1936

Olufunmilayo E Adejumo; Pius S Fasinu; Judith E Odion; Boladale O Silva; Timothy O Fajemirokun

View Article 🔀 PDF 339.13 K

#### Meat Consumption, Related Nutrients, Obesity and Risk of Prostate Cancer: a Case-Control Study in Uruguay

Pages 1937-1945 Eduardo De Stefani; Paolo L Boffetta; Alvaro Ronco; Hugo Deneo-Pellegrini View Article PDF 560.78 K

## Harmal Extract Induces Apoptosis of HCT116 Human Colon Cancer Cells, Mediated by Inhibition of Nuclear Factor-B and Activator Protein-1 Signaling Pathways and Induction of Cytoprotective Genes

Pages 1947-1959 Ayman I Elkady; Rania A Hussein; Sufian M El-Assouli View Article PDF 1.64 M

#### Premature Ejaculation and Erectile Dysfunction in Iranian Prostate Cancer Patients

Pages 1961-1966 Chung-Ying Lin; Andrea Burri; Amir H Pakpour View Article PDF 472.45 K

#### Neural Transdifferentiation: MAPTau Gene Expression in Breast Cancer Cells

Pages 1967-1971

E Lara-Padilla; A Miliar-Garcia; M Gomez-Lopez; P Romero-Morelos; CI Bazan-Mendez; A Alfaro-Rodriguez; M Anaya-Ruiz; K Callender; A Carlos; C Bandala

View Article 🔀 PDF 1.08 M

## Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients

Pages 1973-1978 Ahoua B Effi; N'guiessan A Aman; Baumaney S Koui; Kouadio D Koffi; Zie C Traore; Mohamed Kouyate View Article PDF 490.2 к

# Synergistic Effects of Jerusalem Artichoke in Combination with Pegylated Interferon Alfa-2a and Ribavirin Against Hepatic Fibrosis in Rats

Pages 1979-1985 Nabil Mohie Abdel-Hamid; Ahmed Wahid; Maiiada Hassan Nazmy; Marwa Abdel-Moniem Eisa View Article DPF 1.47 M

#### Screening of BRCA1/2 Mutations Using Direct Sequencing in Indonesian Familial Breast Cancer Cases

Pages 1987-1991 Sumadi Lukman Anwar; Samuel J Haryono; Teguh Aryandono; I Gusti Bagus Datasena View Article PDF 396.9 K

# Telomere-Mitochondrion Links Contribute to Induction of Senescence in MCF-7 Cells after Carbon-Ion Irradiation

Pages 1993-1998 Guo-Ying Miao; Xin Zhou; Xin Zhang; Yi Xie; Chao Sun; Yang Liu; Lu Gan; Hong Zhang View Article PDF 1.14 M

## PHA-Induced Peripheral Blood Cytogenetics and Molecular Analysis: a Valid Diagnostic and Follow-up Modality for Acute Promyelocytic Leukemia Patients Treated with ATRA and/or Arsenic Tri-oxide

Pages 1999-2006 Shahid M Baba; Niyaz A Azad; Zaffar A Shah; Dil Afroze; Arshad A Pandith; Aleem Jan; Sheikh A Aziz; Fayaz A Dar View Article DPF 764.01 K

### Impact of Interactions Between Self-Reported Psychological Stress and Habitual Exercise on the Dietary Intake of Japanese Men and Women: a Large-Scale Cross-Sectional Study

Pages 2007-2017 Kaori Endoh; Kiyonori Kuriki; Nobuhiko Kasezawa; Kazushige Tohyama; Toshinao Goda View Article PDF 280.17 K

## Association of PINX1 but not TEP1 Polymorphisms with Progression to Hepatocellular Carcinoma in Thai Patients with Chronic Hepatitis B Virus Infection

Pages 2019-2025

Methee Sriprapun; Natthaya Chuaypen; Apichaya Khlaiphuengsin; Nutcha Pinjaroen; Sunchai Payungporn; Pisit Tangkijvanich

View Article 🔀 PDF 634.18 K

## Effect of Peripheral Blood CD4 CD25 Regulatory T Cell on Postoperative Immunotherapy for Patients with Renal Carcinoma

Pages 2027-2030 Chao-Hua Zhang; Yan Huang View Article DF 402.19 K

#### International Scoring System in Symptomatic Multiple Myeloma: Experience from a Tertiary Care Center

Pages 2031-2033 Sadia Sultan; Syed Mohammed Irfan; Saira Parveen; Ufaq Taufiq View Article DPF 336.91 K

#### Dietary Patterns and Risk of Breast Cancer in Women in Guilan Province, Iran

Pages 2035-2040 Zahra Ahmadnia; Farideh Hasavari; Zahra Atrkar Roushan; Malahat Khalili View Article 🕒 PDF 472.2 K

#### Incidence and Mortality of Liver Cancer and Their Relationship with Development in Asia

Pages 2041-2047 Maryam Mohammadian; Ali Soroush; Abdollah Mohammadian-Hafshejani; Farhad Towhidi; Fatemeh Hadadian; Hamid Salehiniya

View Article 🔀 PDF 643.13 K

#### Comparison of Ligasure Versus Conventional Surgery for Curative Gastric Cancer Resection: a Meta-Analysis

Pages 2049-2053 Tian-Peng Hu; Xiang-Hui He; Zhao-Wei Meng; Qiang Jia; Jian Tan; Xue Li

View Article 🔀 PDF 727.75 K

#### Lack of Association between an XRCC1 Gene Polymorphism and Colorectal Cancer Survival in Thailand

Pages 2055-2060 Pallop Siewchaisakul; Krittika Suwanrungruang; Kirati Poomphakwaen; Surapon Wiangnon; Supannee Promthet View Article PDF 784.94 K

#### Role of P57KIP2 Immunohistochemical Expression in Histological Diagnosis of Hydatidiform Moles

Pages 2061-2066

Surang Triratanachat; Pattawan Nakaporntham; Patou Tantbirojn; Shanop Shuangshoti; Ruangsak Lertkhachonsuk

View Article DF 3.61 M

#### Risk Factors for Cervical Cancer and CIN3 in Jewish Women in Israel - Two Case Control Studies

Pages 2067-2073

Ravit Bassal; Eduardo Schejter; Rachel Bachar; Tamar Perri; Jacob Korach; Ariella Jakobson-Setton; Liat Hogen Ben-David; Daniel Cohen; Lital Keinan-Boker

View Article PDF 489.96 K

## Knowledge about Risk Factors for Breast Cancer and Having a Close Relative with Cancer Affect the Frequency of Breast Self-Examination Performance

Pages 2075-2081 Angela Gabrielly Quirino Freitas; Mathias Weller View Article PDF 502.21 K

### Isolation and Structure Elucidation, Molecular Docking Studies of Screlotiumol from Soil Borne Fungi Screlotium rolfsii and their Reversal of Multidrug Resistance in Mouse Lymphoma Cells

Pages 2083-2087

Bashir Ahmad; Muhammad Rizwan; Muslim Raza; Sadiq Azam; Shumaila Bashir; Joseph Molnar; Akos Csonka; Diana Szabo

View Article 🔀 PDF 1.15 M

# Mean Platelet Volume as an Independent Predictive Marker for Pathologic Complete Response after Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer

Pages 2089-2092

Hasan Mutlu; Melek Karakurt Eryılmaz; Fatma Yalçcn Musri; Seyda Gunduz; Derya Kıvrak Salim; Hasan Senol Coskun

View Article 🔀 PDF 383.85 K

# Association of Interleukin-27 rs 153109 Single Nucleotide Polymorphism with Spontaneous Resolution of Hepatitis C Virus - Genotype 4a Infection in Egyptian Patients

Pages 2093-2097

Mariam M Fawzy; Ahmed Wahid; Maiiada H Nazmy; Mohamed Hashem; Imam Waked; Sayed F Abdelwahab

View Article 🔀 PDF 512.54 K

# Improved Detection of Helicobacter pylori Infection and Premalignant Gastric Mucosa Using Conventional White Light Source Gastroscopy

Pages 2099-2103

Likit Matrakool; Taweesak Tongtawee; Theeraya Bartpho; Chavaboon Dechsukhum; Ryan A Loyd; Soraya J Kaewpitoon; Natthawut Kaewpitoon

View Article 🔀 PDF 3.95 M

#### Factors Delaying Presentation of Sudanese Breast Cancer Patients: an Analysis Using Andersen's Model

Pages 2105-2110

Alaaddin M Salih; Musab M Alfaki; Dafallah M Alam-Elhuda; Momin M Nouradyem

View Article 🔀 PDF 658.09 K

#### Health Behavior Regarding Liver Flukes among Rural People in Nakhon Ratchasima, Thailand

Pages 2111-2114 Sirinapa Painsing; Anan Sripong; Orramon Vensontia; Prasit Pengsaa; Pontip Kompor; Nusorn Kootanavanichapong; Soraya J Kaewpitoon; Natthawut Kaewpitoon

View Article 🔀 PDF 343.31 K

#### Predictors of Complementary and Alternative Medicine Use by Breast Cancer Patients in Bandung, Indonesia

Pages 2115-2118 Yohana Azhar; Dimyati Achmad; Kiki Lukman; Dany Hilmanto; Teguh Aryandono View Article PDF 343.13 K

#### Alteration of Leptin and Adiponectin in Multistep Colorectal Tumorigenesis

Pages 2119-2123 Name; Teeranut Boonpipattanapong; Anuwat Palanusont; Wanwisa Maneechay; Surasak Sangkhathat View Article PDF 495.4 K

#### Survival of Stomach Cancer Cases in Khon Kaen, Thailand 2000-2012

Pages 2125-2129 Sirinya Nanthanangkul; Krittika Suwanrungruang; Surapon Wiangnon; Supannee Promthet View Article PDF 394.8 K

#### Estimating the Economic Burden of Premature Mortality Caused by Cancer in Iran: 2006-2010

Pages 2131-2136 Behzad Karami-Matin; Farid Najafi; Satar Rezaei; Ardashir Khosravi; Moslem Soofi View Article PDF 528.63 K

#### Radiological Downstaging with Neoadjuvant Therapy in Unresectable Gall Bladder Cancer Cases

Pages 2137-2140 Sushma Agrawal; Lalit Mohan; Chandan Mourya; Zafar Neyaz; Rajan Saxena View Article PDF 1.15 M

#### Nurse Attitude-Related Barriers to Effective Control of Cancer Pain among Iranian Nurses

Pages 2141-2144

Name; Robab Mohamadian; Azad Rahmani; Hussein Fizollah-zadeh; Franak Jabarzadeh; Arman Azadi; Hussein Rostami

View Article 🔀 PDF 353.61 K

### Distribution of Glutathione S-Transferase Omega Gene Polymorphism with Different Stages of HBV Infection Including Hepatocellular Carcinoma in the Egyptian Population

Pages 2145-2150

Nadia Z Shaban; Halima H Salem; Mohamed A Elsadany; Bahy A Ali; Ehab M Hassona; Fayed AK Mogahed

View Article 🔀 PDF 706.5 K

### Scabraside D Derived from Sea Cucumber Induces Apoptosis and Inhibits Metastasis via iNOS and STAT-3 Expression in Human Cholangiocarcinoma Xenografts

Pages 2151-2157

Kanjana Assawasuparerk; Thanakorn Rawangchue; Rassameepen Phonarknguen

View Article 🔀 PDF 1.35 M

#### Diagnosis and Monitoring of Chronic Myeloid Leukemia: Chiang Mai University Experience

Pages 2159-2164

Adisak Tantiworawit; Supanat Kongjarern; Ekarat Rattarittamrong; Suree Lekawanvijit; Kanokkan Bumroongkit; Nonglak Boonma; Thanawat Rattanathammethee; Sasinee Hantrakool; Chatree Chai-Adisaksopha; Lalita Norasetthada

View Article DF 456.92 K

# Hepatocellular Carcinoma in a Tertiary Referral Hospital in Indonesia: Lack of Improvement of One-Year Survival Rates between 1998-1999 and 2013-2014

Pages 2165-2170 Imelda M Loho; Irsan Hasan; C Rinaldi A Lesmana; Esthika Dewiasty; Rino A Gani

View Article 🔀 PDF 472.58 K

#### Trend of Cancer Incidence in Nepal from 2003 to 2012

Pages 2171-2175 Krishna Kanta Poudel; Zhibi Huang; Prakash Raj Neupane View Article PDF 673.32 K

## Predictive Value of Malignancy Risk Indices for Ovarian Masses in Premenopausal and Postmenopausal Women

Pages 2177-2183 Sinem Ertas; Fisun Vural; Ertugrul Can Tufekci; Ahmet Candost Ertas; Gultekin Kose1; Nurettin Aka View Article DPF 572.51 K

# Sensitive and Noninvasive Detection of Aberrant SFRP2 and MGMT-B Methylation in Iranian Patients with Colon Polyps

Pages 2185-2193

M Alizade Naini; P Mokarram; S Kavousipour; N Zare; A Atapour; M Hassan Zarin1; G Mehrabani; M Borji

View Article DPF 592.61 K

# Clinicopathological Profile of Breast Cancer Patients at a Tertiary Care Hospital in Marathwada Region of Westen India

Pages 2195-2198

Unmesh Vidyadhar Takalkar1; Shilpa Balaji Asegaonkar; Umesh Kulkarni; Mamta Saraf; Suresh Advani

View Article 🔀 PDF 389.76 K

## Prediction and Analysis of Breast Cancer Related Deleterious Non-Synonymous Single Nucleotide Polymorphisms in the PTEN Gene

Pages 2199-2203 C Kumaraswamy Naidu; Y Suneetha View Article PDF 421.29 K

### Surveillance of Populations at Risk of Cholangiocarcinoma Development in Rural Communities of Thailand Using the Korat-CCA Verbal Screening Test

Pages 2205-2209

Soraya J Kaewpitoon; Ratana Rujirakul; Ryan A Loyd; Sukij Panpimanmas; Likit Matrakool; Taweesak Tongtawee; Porntip Kompor; Jun Norkaew; Wasugree Chavengkun; Parichart Wakkhuwattapong; Jirawoot Kujapun; Sukanya Ponphimai; Tanida Phatisena; Thawatchai Eaksunti; Poowadol Polsripradist; Apinya Joosiri; Inchat Sukkasam; Natnapa Padchasuwan; Natthawut Kaewpitoon

View Article 🔀 PDF 1.46 M

#### Post-Loop Electrosurgical Excision Procedure Complications in Srinagarind Hospital

Pages 2211-2215

Pimjai Maleerat; Bandit Chumworathayi; Chumnan Kietpeerakool; Sanguanchoke Luanratanakorn; Amornrat Temtanakitpaisan

View Article 🔀 PDF 357.71 K

## VEGFR2 Expression in Head and Neck Squamous Cell Carcinoma Cancer Cells Mediates Proliferation and Invasion

Pages 2217-2221 Hui-Min Xu; Jian-Guo Zhu; Lian Gu; Song-Qun Hu; Hao Wu2

View Article 🔀 PDF 4.42 M

### Survival Rates for Breast Cancer in Iranian Patients: a Meta- Analysis

Pages 2223-2227 Mitra Rahimzadeh; Mohamad Amin Pourhoseingholi; Behrooz Kavehie View Article PDF 454.15 K

### Is Health Locus of Control a Modifying Factor in the Health Belief Model for Prediction of Breast Self-Examination?

Pages 2229-2233

Rahim Tahmasebi; Azita Noroozi

View Article PDF 373.02 K

## Preventive Effects of Spirogyra neglecta and a Polysaccharide Extract against Dextran Sodium Sulfate Induced Colitis in Mice

Pages 2235-2245 Sirinya Taya; Anna Kakehashi; Rawiwan Wongpoomchai; Min Gi; Naomi Ishii; Hideki Wanibuchi View Article DPF 2.37 M

#### I Do Not Even Say "It" - a Mixed Methods Study on Breast Cancer Awareness of Omani Women

Pages 2247-2254 Esra Alkhasawneh; Saad T Siddiqui; Michael Leocadio; Vidya Seshan; Yahya Al-Farsi; Mansour S Al-Moundhri View Article DPF 727.21 K

# Incidentally Detected Adenocarcinoma Prostate in Transurethral Resection of Prostate Specimens: a Hospital Based Study from India

Pages 2255-2258

Jophy Varghese; Priya Mariam Kuruvilla; Nisarg Mehta2; Ranjeet Singh Rathore; Manas Babu; Devesh Bansal; Biju Pillai; Mohan P Sam; H Krishnamorthy

View Article 🔀 PDF 384.14 K

### Relation between Mammographic Parenchymal Patterns and Breast Cancer Risk: Considering BMI, Compressed Breast Thickness and Age of Women in Tabriz, Iran

Pages 2259-2263 Parinaz Mehnati; Hamed Alizadeh; Haleh Hoda

View Article 🔀 PDF 467.18 K

## The rs61764370 Functional Variant in the KRAS Oncogene is Associated with Chronic Myeloid Leukemia Risk in Women

Pages 2265-2270

Humberto Gutiérrez-Malacatt; Manuel Ayala-Sanchez; Xochitl Aquino-Ortega; Jacqueline Dominguez-Rodriguez; Adolfo Martinez-Tovar; Irma Olarte-Carrillo; Angelica Martinez-Hernandez; Cecilia Contreras-Cubas C; Lorena Orozco; Emilio J Cordova

View Article 🔀 PDF 550.75 K

### 5-Aminolevulinic Acid Fluorescence in Detection of Peritoneal Metastases

Pages 2271-2275

Yutaka Yonemura; Emel Canbay; Haruaki Ishibashi; Eisei Nishino; Yoshio Endou; Shouzou Sako; Shun-Ichirou Ogura

View Article DPF 1003.73 K

### Formulation and Cytotoxicity of Ribosome-Inactivating Protein Mirabilis Jalapa L. Nanoparticles Using Alginate-Low Viscosity Chitosan Conjugated with Anti-Epcam Antibodies in the T47D Breast Cancer Cell Line

Pages 2277-2284

Psycha Anindya Wicaksono; Sismindari Name; Ronny Martien; Hilda Ismail

View Article 🔀 PDF 1.04 M

# Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: Is It Different between Over and Under 50 Years of Age?

Pages 2285-2289

Ahmad Monabati; Amir Vahedi; Akbar Safaei; Sadat Noori; Maral Mokhtari; Leila Vahedi; Mehdi Zamani

View Article 🔀 PDF 765.58 K

### Virtual Screening Approaches in Identification of Bioactive Compounds Akin to Delphinidin as Potential HER2 Inhibitors for the Treatment of Breast Cancer

Pages 2291-2295

Kavisha Patidar; Aruna Deshmukh; Srinivas Bandaru; Chandana Lakkaraju; Amandeep Girdhar; Gutlapalli VR; Tushar Banerjee; Anuraj Nayarisseri; Sanjeev Kumar Singh

View Article DPF 1.2 M

# Interferon Induced Transmembrane Protein-1 Gene Expression as a Biomarker for Early Detection of Invasive Potential of Oral Squamous Cell Carcinomas

Pages 2297-2299 Arvind Ramanathan; Arvind Ramanathan View Article Δ PDF 670.31 κ

### Are Biomarkers Predictive of Anthracycline-Induced Cardiac Dysfunction?

Pages 2301-2305 Abhidha Malik; Pamela Alice Jeyaraj; Rajneesh Calton; Bharti Uppal; Preety Negi; Abhishek Shankar; Jaineet Patil; Manmohan Kishan Mahajan

View Article 🔀 PDF 370.98 K

### Acute Lymphoblastic Leukemia in Adults - an Analysis of 51 Cases from a Tertiary Care Center in Pakistan

Pages 2307-2309 Sadia Sultan; Syed Mohammed Irfan; Saira Parveen1; Sanober Mustafa2

View Article 🔀 PDF 344.23 K

# Reversal of Multidrug Resistance and Computational Studies of Pistagremic Acid Isolated from Pistacia integerrima

Pages 2311-2314

Abdur Rauf; Ghias Uddin; Muslim Raza; Aftab Ahmad; Noor Jehan; Bashir Ahmad; Muhammad Nisar; Joseph Molnar; Akos Csonka; Diana Szabo; Ajmal Khan; Umar Farooq; Mah Noor

View Article 🔀 PDF 739.9 K

#### Influence of Religious Beliefs on the Health of Cancer Patients

Pages 2315-2320 Tai-Jung Tsai; Ue-Lin Chung; Chee-Jen Chang; Hsiu-Ho Wang View Article PDF 457.84 к

### Lack of Variation in Inflammatory Hematological Parameters between Benign Nodular Goiter and Papillary Thyroid Cancer

Pages 2321-2323

Selcuk Yaylaci; Onder Tosun; Orhan Sahin; Ahmet Bilal Genc; Ercan Aydin; Gokhan Demiral; Fatma Karahalil; Serdar Olt; Hasan Ergenc; Ceyhun Varim

View Article 🔀 PDF 342.01 K

#### Randomized-Control Screening Trials to Lower Gall Bladder Cancer Mortality in High Risk Populations

Pages 2325-2327 Manigreeva Krishnatreya; Amal Chandra Kataki View Article 译 PDF 330.15 K

#### Prescription Errors with Chemotherapy: Quality Improvement through Standardized Order Templates

Pages 2329-2336 Aline Saad; Caroline A. Der-Nigoghossian; Rachel Njeim; Riwa Sakr; Pascale Salameh; Marcel Massoud View Article PDF 516 K

#### Educational Utilization of Microsoft Powerpoint for Oral and Maxillofacial Cancer Presentations

Pages 2337-2339 Francisco Samuel Rodrigues Carvalho; Filipe Nobre Chaves; Eduardo Costa Studart Soares; Thyciana Rodrigues Ribeiro; Cristiane Sa Roriz Fonteles; Fabio Wildson Gurgel Costa

View Article 🔀 PDF 753.83 K

### Does Indian Myelodysplastic Syndrome Have a Biology Different from That in the West?

Pages 2341-2342 Rekha Chaubey; Sudha Sazawal; Manoranjan Mahapatra; Sunita Chhikara; Renu Saxena View Article DPF 354.77 к

### Outcome of Inversion 16 in TKD Positive and Negative Acute Myeloid Leukemia Patients

Pages 2343-2344

Sadaf Shahab; Danish Zahid; Shariq Ahmed; Muhammad Nadeem; Tasneem Farzana; Mehwesh Taj; Nuzhat Ahmed; Tahir S Shamsi

View Article DF 392.77 K

### Tobacco Control in India - Just a Legislative Measure?

Pages 2345-2346

Aman Chowdhry

View Article DPF 270.86 K

### Sharon Whelan

Pages 2347-2348 Max Parkin

View Article 🔀 PDF 738.87 K

## **RESEARCH ARTICLE**

## Celecoxib, a COX-2 Selective Inhibitor, Induces Cell Cycle Arrest at the G2/M Phase in HeLa Cervical Cancer Cells

#### **Agustina Setiawati**

#### Abstract

Celecoxib, a selective inhibitor of COX-2, showed cytotoxic effects in many cancer cell lines including cervical cancer cells. This study investigated the effect of celecoxib on cell cycle arrest in HeLa cervical cancer cells through p53 expression. *In vitro* anticancer activity was determined with the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) method. A double staining method was applied to investigate the mechanism of cell death, cell cycling was analyzed by flow cytometryand immunocytochemistry was employed to stain p53 expression in cells. Celecoxib showed strong cytotoxic effects and induced apoptosis with an IC<sub>50</sub> value of 40  $\mu$ M. It induced cell cycle arrest at G2/M phase by increasing level of p53 expression on HeLa cells.

Keywords: Celecoxib - HeLa cells - apoptosis - cell cycle - p53

Asian Pac J Cancer Prev, 17 (4), 1655-1659

#### Introduction

Cervical cancer is the third most common diagnosed cancer and leading cause of the death among female worldwide (Vici et al., 2014; Torre et al., 2015). (Kimman et al., 2012) reported that it was the second highest incidence of cancer in ASEAN female. in Indonesia, it was ranked as the third most commonly caused of female death of cancer. The burden of this disease is majority in low and middle income country (Sahasrabuddhe et al., 2013). The pattern of cervical cancer shifted from more developed to less developed country (Torre et al., 2015). Since the incidence is rapidly rising, many drugs were developed to prevent and treat cervical cancer. Many studies work on new cervical cancer drugs by targeting specific biomarker without effecting normal cells.

Drug discovery and development is a very complex process and costly. It needs approximately US\$ 802 million for 10 to 20 years to bring a drug from laboratory to market (Dickson and Gagnon, 2009). Drug repurposing is one of alternative approach to increase the effectivity of drug discovery (Gupta et al., 2013). Celecoxib(4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfon-amide), a selective cyclooxygenase-2 (COX-2) inhibitor, is a potentially developed as anticancer in cervical cancer. It was first launched by US Food and Drug Administration in 2009 to treat osteoarthritis (Audo et al., 2007; Zweers et al., 2011). COX-2 expression is linked to cancer progression including cervical cancer. When Human Papiloma Virus (HPV) infected cervical cells, it inserted E6 and E7 oncogene that induced COX-2 expression in cells (Kim et al., 2013).

In vitro studies reported celecoxib revealed cytotoxic activity on cervical, liver, colon, breast, gastric and prostate cancer cells (Hsu et al., 2000; Kim et al., 2004, 2007; Ang et al., 2012; Wang et al., 2009, 2013; Chu et al., 2013). In cervical cancer cells, it induced cell cycle arrest at G1 and G2/M phase depended on its concentration (Kim and Pyo, 2013). However, the molecular mechanism of celecoxib through p53 was still unclear. Protein p53 is a key inducer of apoptosis and cell cycle arrest process (Nair et al., 2003; Li et al., 2012) by degrading E6 and E7 oncogene (Nair et al., 2003). p53, a tumor suppressor gene, was frequently mutated in several cancer cell lines but the mutation of p53 was low frequent in cervical cancer (Pinheiro and Villa, 2001). p53 is potential biomarker that could be investigated in HeLa cells. This work focused on molecular mechanism of celecoxib on HeLa cervical cancer cell line by inducing apoptosis and cell cycle arrest through p53 expression.

#### **Materials and Methods**

#### Cytotoxic, Apoptosis, Flowcytometry and Immunocytochemistry

The sample of this study was prepared from celecoxib (Sigma) with 99.995% purity while cisplatin as positive control was prepared from Cisplatin Kalbe. This subject of this study was HeLa cells, a cell culture collection of Parasitology Department, Faculty of Medicine, Universitas Gadjah Mada. The cells were maintained in Dubelcco Modified Eagle Media (Gibco) containing Fetal

Department of Drug Design and Discovery, Faculty of Pharmacy, Universitas Sanata Dharma, Yogyakarta, Indonesia \*For correspondence: nina@usd.ac.id

#### Agustina Setiawati

Bovine Serum (FBS) 10% (v/v) (Gibco) and penicilinstreptomycin 1% (v/v) (Gibco). Cytotoxic assay was measured by 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) (Sigma) method while the apoptosis assay was examined by ethidium bromide and acridine orange (Sigma) staining. Propidium iodide reagent contained 0.1% triton X (E.Merck, Germany), 0.2% RNAse and 5% propidium iodide (Sigma) in Phosphate Buffer Saline (PBS). Immunocytochemistry used p53 primary antibody purchased form Novus Bio NB 200-103, while the universal secondary antibody was derived from Starr Trek Universal HRP Detection System No.901-STUHRP700-090314. All culture plates used in this study were Iwaki® and all tips and micro tubes were supplied by Axigen®.

#### MTT cytotoxic assay

Cytotoxic assay was designed based on previous study on HeLa cells (Yuliani et al., 2015). The cells were cultured in culture tissue flask until 70-80% confluent, and then  $5x10^3$  cells were seeded into 96-well plate. The plate was incubated at 37°C and 5% CO<sub>2</sub> for 24 hours. The medium was removed and the cells were rinsed twice by using PBS. The stock solution of celecoxib was prepared by dissolving them into DMSO and diluted them in medium into various concentrations. Each concentration  $(100 \,\mu \text{L/well})$  was added into 96-well plate and measured in triplicates. Later, the plate was incubated at 37°C and under 5% CO<sub>2</sub> for 24 hours. The medium was removed and 10% MTT containing medium was added into each well. The plate was further incubated in the same as previous condition for 4 hours. At the end of incubation time, 100  $\mu$ L SDS was added to each well to dissolve formazan crystals. The plate was incubated in dark room for 12-24 hours and formazan crystals were measured by using ELISA reader at a wavelength of 595 nm.

#### Apoptosis induction assay

HeLa cells were seeded into coverslips in 24-well plate (5x104/well). The cells were adapted at 37oC and 5% CO2 for 24 hours. The medium was removed and twice rinsed by using PBS. The celecoxib and cisplatin at 40  $\mu$ M concentration were added into the plate and incubated in the same condition as previously described. The medium was removed from the cells and rinsed by using PBS. The coverslips transferred to object glasses, then acridine orange-ethidium bromide (AE) was dropped into the coverslips. The cells were immediately observed under fluorescence microscope (Yuliani et al., 2015).

#### Cell cycle analysis

HeLa cells were seeded in a 6 well plate at a density of 1 x 10<sup>6</sup> cells each well. After 24 hours incubation, celecoxib and cisplatin at concentration 40  $\mu$ M were added to the respective flask and incubated for 12 and 24 hours. The cells were removed and harvested from flask using tripsin. After incubation, the cells were centrifuged at 2000 rpm for 3 minutes. The cells were washed using cold phosphate buffer saline (PBS) three times. The pellets were resuspended in 500  $\mu$ L propidium iodine (10  $\mu$ g/mL) containing 300 $\mu$ g/mL RNase (Sigma, MO, USA). The cells were incubated at 37°C for 10 minutes in waterbath. Cell suspension was homogenized and transferred in flowcyto tube. Then the cells were analyzed by flowcytometer.

#### Immunocytochemistry assay

HeLa cells were cultured in 6-well plate and incubated under 5% CO<sub>2</sub> and 37°C for 24 hours. Celecoxib and cisplatin at 40  $\mu$ M concentration were added to the cells and incubated for further 24 hours. At the end of incubation time, cells were collected and washed by PBS. The cells were suspended in medium, placed and fixed in object glass for 5 minutes. Hydrogen peroxidase was dropped into the object glass and incubated at room temperature for 10-15 minutes. The cells were washed twice with PBS and monoclonal antibody of p53 was added into the cells and incubated at least for an hour at room temperature. The cells were washed three times with PBS and added with secondary antibody, incubated at room temperature for ten minutes, and washed four times with PBS. The solution of 3, 3'-diaminobenzidine (DAB), as chromogen, was added to the cells and incubated for 3-8 minutes. Finally, the cells were washed with distilled water and added with hematoxylin solution followed by 3-4 minutes incubation. The expression of p53 was observed under inverted microscope (Yuliani et al., 2015).

#### Data analysis

To calculate  $IC_{50}$  of celecoxib and cisplatin, the viability data was plotted in linear regression using Microsoft Excel 2013. Apoptotic, necrotic and living cells was qualitatively counted in three different areas of the object glass. This analysis was performed in triplicate of each treatment. Cell cycle distribution was calculated from 10,000 cells with ModFit LT 3.0 TM software using FACScaliber. The number of p53 expressing cells was qualitatively analyzed.

#### **Results**

This study determined anticancer activity of celecoxib on HeLa cervical cancer cells by arresting cell cycle through inducing p53 expression. Cytotoxic effect was assessed with MTT assays that measured absorbance of



Figure 1. Celecoxib and Cisplatin Effect on HeLa Cells Viability and Morphology. (a) Untreated Cells, (b) 40  $\mu$ M Celecoxib, (c) 40  $\mu$ M Cisplatin. Red arrows showed the death cells in population



Figure 2. Observation of Cells on Double Staining Method Under Flourecence Microscope Using 400X Magnification. (A)Untreated cells, (B) Celecoxib 40  $\mu$ M (C) Cisplatin 40  $\mu$ M. White arrows showed living cells and yellow arrows showed apoptotic cells



Figure 3. Analysis of Cell Cycle Progression. HeLa cells were (A) Untreated, (B) 40  $\mu$ M celecoxib and (C) 40  $\mu$ M cisplatin. The cells were harvested after 24 hours then they were analyzed for DNA content. The distribution and percentage of cells in pre-phase, G1, S and G2/M phase of the cell cycle were indicated



Figure 4. The Observation of p53 Expression on HeLa cells by Using Imunocytochemistry Method Under Light Microscope in 400x Magnification. (A)Untreated cells (B) Cells treated with 40  $\mu$ M celecoxib. (C) Cells treated with 40  $\mu$ M cisplatin. Brown colour (black arrows) in cells refer to p53 expression

formazan complex at 595 nm that equaled to the number of living cells. As presented in Figure 1, celecoxib showed dose dependent cytotoxic activity ( $R_2$ =0.9924) on HeLa cells with IC<sub>50</sub> 43  $\mu$ M, respectively. Cisplatin was used as positive control since it was widely used as therapy in cancer patient (Dasari and Tchounwou, 2014; Vici et al., 2014).

Based on our previous work, cisplatin performed cytotoxic activity and apoptosis induction on HeLa cells with IC<sub>50</sub> 40  $\mu$ M (Yuliani et al., 2015). Celecoxib and cisplatin changed HeLa cells morphology and induced cell death at concentration 40  $\mu$ M. Double staining method investigated the mechanism of cells death (Figure 2). Celecoxib and cisplatin induced apoptosis in HeLa cells. This method clearly identified apoptosis stage insignificant different from flowcytometry method (Liu et al., 2015).

Cell cycle analysis counted that HeLa cells were accumulated on G2/M phase in celecoxib (61.70%) and cisplatin treatment (56.65%) compare to untreated cells (17.41%) (Figure 3). Molecular mechanism of cell cycle arrest was determined by immunocytochemistry method. Since p53 is a major regulator of apoptosis pathway and cell cycle arrest, further we investigated p53 expression. HeLa cells that express p53 were stained as intense brown color in nuclei while none were stained as blue color. Qualitative analysis of Figure 4 indicated that both of celecoxib and cisplatin increased p53 expression. This data suggested that cytotoxic activity of celecoxib induced cell cycle arrest through inducing p53 expression in HeLa cells.

#### Discussion

This pre-clinical study investigated celecoxib repurposing to be anticancer drug on cervical cancer. Previous research revealed celecoxib had cytotoxic effect and induced apoptosis in HeLa cervical cancer cells (Kim et al., 2007, 2004). Non Steroid Inflammation Drugs (NSAIDs), including selective COX-2 inhibitor, have been associated with reduced incidence and mortality in many cancer cells (Gurpinar et al., 2013; Setiawati et al., 2016). Since it inhibited COX-2 expression, celecoxib reduced prostaglandin E2 and thromboxane A2 that play important role in cell proliferation, invasion and survival (Allaj et al., 2013). Moreover, molecular mechanism was not always associated with COX-2 expression (Kang et al., 2009; Kim et al., 2004). The study of Ang and colleagues (2012) showed by reducing COX-2, celecoxib sensitized radiotherapy in HeLa cells (Ang et al., 2012). However, COX-2 expression increased survival on cervical cancer patients (Doll et al., 2013). Therefore, other proteins might interference anticancer activity of celecoxib.

In this study, cisplatin was used as positive control since it was clinically used in cervical cancer therapy both single and combination (Vici et al., 2014; Grigsby et al., 2013). It revealed drug resistance (Galluzzi et al., 2014) and severe side effect such as kidney toxicity, allergic reaction, immunity problem, gastrointestinal disorder, hemorrhage and hearing loss (Dasari and Bernard Tchounwou, 2014). Celecoxib performed strong cytotoxic activity and induced apoptosis on HeLa cells (Figure 1

#### Agustina Setiawati

and 2). Based on IC<sub>50</sub> value, celecoxib (IC<sub>50</sub>=43  $\mu$ M) had strong cytotoxic activity equal to cisplatin in HeLa cells.

Cell cycle regulation is an essential target in HPVassociated carcinogenesis (Fernandes and Syrjanen, 2003). Flow cytometry data showed that HeLa cells were primarily arrested in the G2/M phase due to celecoxib and cisplatin treatment (Figure 3). Since G1 and G2/M checkpoint in cell cycle are interfered by HPV in cervical cancer (Fernandes and Syrjanen, 2003), anticancer drugs possibly address on both of cell cycle. Other effects of celecoxib and cisplatin on cell cycle progression were reported it induced cell cycle arrest in different phase. At different concentration, cisplatin induced G1 arrest in HeLa cells (Larasati et al., 2014). Celecoxib induced different cell cycle arrest at G1 phase in bladder, glial and colon cancer (Gee et al., 2009; Kang et al., 2009; Kim and Pyo, 2013). In cervical cancer, celecoxib induced cell cycle arrest in G1 and G2/M phase depended on its concentration (Kang et al., 2009).

To observe molecular target, this study targeted p53 as a key protein that responsible to apoptosis and cell cycle arrest. Vast efforts based on p53 activation had been successfully treat cancer (Lane et al., 2010; Chen et al., 2010), especially cervical cancer (Lee et al., 2006). Both of celecoxib and cisplatin induced p53 expression in HeLa cells to arrest cell cycle at G2/M phase (Figure 4). This finding opened an interesting question whether p53 expression involved in apoptosis and cell cycle arrest in HeLa cells. Based on our p53 immunocytochemistry data, both of celecoxib and cisplatin executed apoptosis and cell cycle arrest by involving p53. Stabilization of p53 possibly pushed cell cycle arrest at G2/M phase and apoptosis in HeLa cells (Larasati et al., 2014). When p53 is activated, it stimulates cell cycle arrest and induces apoptosis (Pflaum et al., 2014). Active form of p53 activated several genes which were involved in G1, S and G2/M arrest. Therefore, it might induce multiple cell cycle arrest (Garofalo and Surmacz, 2006). Another possible molecular mechanism was reported by Kim and colleagues (2007) that celecoxib induced apoptosis in cervical cancer cells through GADD135, a transcription factor. Target proteins which are activated by p53, involving apoptosis and cell cycle arrest HeLa cells, are suggested to be observed in further study to settle detailed molecular pathway of celecoxib.

In conclusion, celecoxib induced cell cycle arrest at G2/M phase through inducing p53 expression on HeLa cervical cancer cells. It is interesting to investigate p53-dependent molecular pathway in further study.

#### Acknowledgements

This work was funded by Institute for Research and Public Affair, Universitas Sanata Dharma (Internal Research Grant No.025/Penelitian Internal USD/ STP/2015).

#### References

Allaj V, Guo C, Nie D (2013). Non-steroid anti-inflammatory drugs, prostaglandins, and cancer. *Cell Biosci*, 3, 8.Ang AHW, Ian XYT, Yu JJ, et al (2012). Celecoxib Radiosensitizes the Human Cervical Cancer HeLa Cell Line via a Mechanism Dependent on Reduced Cyclo-oxygenase-2 and Vascular Endothelial Growth Factor C Expression. *J Internl Med Res*, **40**, 56-66.

- Audo R, Deschamps V, Hahne M, Combe B, et al (2007). Apoptosis is not the major death mechanism induced by celecoxib on rheumatoid arthritis synovial fibroblasts. *Arthritis Res Ther*, **9**, 128.
- Chen F, Wang W, El-Deiry WS (2010). Current strategies to target p53 in Cancer. *Biochemical Pharmacol*, **80**, 727-30.
- Chu T, Chan H, Kuo H, Liu L, et al (2013). Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN. *Oncotarget*, **5**, 1475-90.
- Dasari S, Tchounwou BP (2014). Cisplatin in Cancer therapy: Molecular mechanisms of action. *Eur J Pharmacol*, **740**, 364-78.
- Doll CM, Winter K, Gaffney DK et al (2013). COX-2 Expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: A quantitative immunohistochemical analysis of RTOG C0128. *Int J Gynecol Cancer*, **23**, 176-83.
- Fernandes SM, Syrjanen KJ (2003). Regulation of cell cycles is of key importance in human papillomavirus (HPV)-asociated cervical carcinogenesis. *Sao Paulo Med J*, **121**, 128-32.
- Galluzzi L, Vitale I, Michels J, Brenner C, et al (2014). Systems biology of cisplatin resistance: past, present and future. *Cell Death Dis*, 5, 1257.
- Garofalo C, Surmacz E (2006). Leptin and cancer. *J Cell Physiol*, **207**, 12-22.
- Grigsby PW, Zighelboim I, Powell MA, et al (2013). *In vitro* chemoresponse to cisplatin and outcomes in cervical cancer. *Gynecol Oncol*, **130**, 188-91.
- Gupta SC, Sung B, Prasad S, Webb LJ, et al (2013). Cancer drug discovery by repurposing: Teaching new tricks to old dogs. *Trends Pharmacol Sci*, **34**, 508-17.
- Gurpinar E, Grizzle WE, Piazza G (2013). COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs. Front Oncol, 3, 1-18.
- Hsu AL, Ching TT, Wang DS, et al (2000). The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. *J Biol Chem*, **275**, 11397-1403.
- Kang KB, Zhu C, Yong SK, et al (2009). Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy. *Molecular Cancer*, 8, 66.
- Kang MK, Park W, Choi YL, et al (2009). The effect of cyclooxygenase-2 expression on tumor volume response in patients treated with radiotherapy for uterine cervical cancer. *J Korean Med Sci*, 24, 1170-76.
- Kim HS, Kim T, Kim M, et al (2013). Cyclooxygenase-1 and -2: Molecular Targets for Cervical Neoplasia. J Cancer Prevent, 18. 123- 34.
- Kim SH, Hwang CI, Juhnn YS, et al (2007). Erratum: GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells. *Carcinogenesis*, 28, 223-31.
- Kim SH, Song SH, Kim SG, et al (2004). Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J Cancer Res Clin Oncol, 130, 551-60.
- Kim YM, Pyo H (2013). Different Cell Cycle Modulation by Celecoxib at Different Concentrations. *Cancer Biother Radiopharm*, 28, 138-45.
- Kimman M, Norman R, Jan S, et al (2012). The burden of cancer in member countries of the association of southeast asian nations (ASEAN). Asian Pac J Cancer Prev, 13, 411-20.
- Lane DP, Cheok CF, Lain S (2010). p53-based cancer therapy.

Cold Spring Harb Perspect Biol, 2, 1222.

- Larasati YA, Putri DPP, Utomo RY, et al (2014). Combination of cisplatin and cinnamon essential oil inhibits hela cells proliferation through cell cycle arrest. *J App Pharm Sci*, 4, 14-9.
- Lee YS, Bae SM, Kwak SY, et al (2006). Cell cycle regulatory protein expression profiles by adenovirus p53 infection in human papilloma virus-associated cervical cancer cells. *Cancer Res Treat*, **38**, 168-77.
- Li T, Kon N, Jiang L, et al (2012). Tumor suppression in the absence of p53-mediated cell cycle arrest, apoptosis, and senescence. *Cell*, **149**, 1269-83.
- Liu K, Liu PC, Liu R, et al (2015). Dual AO/EB staining to detect apoptosis in osteosarcoma cells compared with flow cytometry. *Med Sci Monit Basic Res*, **21**, 15-20.
- Nair P, Somasundaram K, Krishna S (2003). Activated notch1 inhibits p53-induced apoptosis and sustains transformation by human papillomavirus type 16 E6 and E7 oncogenes through a activated notch1 inhibits p53-induced apoptosis and sustains transformation by human papillomavirus type 16 E6 and E7. *J Virol*, **77**, 7106-112.
- Pflaum J, Schlosser S, Müller M (2014). p53 family and cellular stress responses in cancer. *Frontier Oncol*, **285**, 1-15.
- Pinheiro NA, Villa LL (2001). Low frequency of p53 mutations in cervical carcinomas among Brazilian women. *Brazilian J Med Biol Res*, **34**, 727-33.
- Torre LA, Bray F, Siegel RL, et al (2015). Global Cancer Statistics, 2012. CA Cancer J Clin, 15, 87-108
- Vici P, Mariani L, Pizzuti L, et al (2014). Emerging biological treatments for uterine cervical carcinoma. J Cancer, 5, 86-97.
- Sahasrabuddhe VV, Parham GP, Mwanahamuntu MH, et al (2013). Cervical cancer prevention in low- and middleincome countries: Feasible, Affordable, Essential. *Cancer Prev Res (Phila)*, 5, 11-17.
- Setiawati A, Immanuel H, Utami MT (2016). Typhonium flagelliforme lodd. blume leaf extract inhibits COX-2 expression on WiDr colon cancer cells. *Asian Pac J Trop Biomed*, **6**.
- Wang L, Liu LH, Shan BE, et al (2009). Celecoxib promotes apoptosis of breast cancer cell line MDA-MB-231 through down-regulation of the NF-kappa B pathway. *Chin J Cancer*, 28, 6.
- Wang Y, Niu X, Yang L, et al (2013). Effects of Celecoxib on Cycle Kinetics of Gastric Cancer Cells and Protein Expression of Cytochrome C and Caspase-9. Asian Pac J Cancer Prev, 14, 2343-47.
- Yuliani SH, Anggraeni CD, Sekarjati W, et al (2015). Cytotoxic Activity of Anredera cordifolia Leaf Extract on HeLa Cervical Cancer Cells through p53-Independent Pathway. Asian J Pharm Clin Res, 8, 328-31.
- Zweers MC, de Boer TN, van Roon J, et al (2011). Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. *Arthritis Res Ther*, **13**, 239.